Similar companies
Income Statement (EUR)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 13.2B | 22.7% |
| Gross Profit | 9.76B | 26% |
| Cost of Revenue | 3.41B | 14% |
| Operating expense | 6.14B | 2.1% |
| Net Income | 2.8B | 28.9% |
| EBITDA | 4.21B | 123.1% |
Balance Sheet (EUR)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 130B | 3.9% |
| Total Liabilities | 56.3B | 2.9% |
| Total Equity | 73.3B | 4.6% |
| Shares Outstanding | 2.47B | 0% |
Cash Flow (EUR)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | 3.75B | 156.5% |
| Cash from financing | -1.15B | 70.2% |
Financial Highlights for Sanofi in Q3 '25
Sanofi reported a revenue of 13.2B, which is a 22.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 9.76B, marking a 26% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.41B, a 14% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 6.14B, showing a -2.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 2.8B, showing a -28.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 4.21B, showing a 123.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Sanofi faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
